Gallagher Fiduciary Advisors LLC Buys New Holdings in CVS Health Corporation $CVS

Gallagher Fiduciary Advisors LLC purchased a new stake in shares of CVS Health Corporation (NYSE:CVS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,492 shares of the pharmacy operator’s stock, valued at approximately $672,000.

A number of other large investors also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its holdings in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares during the period. Swiss RE Ltd. acquired a new position in CVS Health during the fourth quarter valued at approximately $26,000. Kilter Group LLC purchased a new stake in CVS Health during the second quarter worth approximately $27,000. Sankala Group LLC acquired a new stake in shares of CVS Health in the fourth quarter worth $28,000. Finally, Global Trust Asset Management LLC raised its stake in shares of CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after acquiring an additional 300 shares during the period. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Performance

NYSE:CVS opened at $92.95 on Wednesday. The firm has a 50-day moving average of $101.73 and a two-hundred day moving average of $89.20. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a market cap of $118.88 billion, a P/E ratio of 24.59, a PEG ratio of 0.86 and a beta of 0.61. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same period in the previous year, the company earned $1.81 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, research analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Thursday, July 23rd. CVS Health’s payout ratio is 70.37%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on CVS shares. Mizuho upped their price target on shares of CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. UBS Group boosted their price objective on CVS Health from $122.00 to $126.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Royal Bank Of Canada upped their target price on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. Truist Financial increased their target price on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Finally, JPMorgan Chase & Co. boosted their price target on CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Twenty-two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average target price of $107.17.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.